The Pharma Letter1d
Latest Teva data in schizophrenia for long-acting injectable of olanzapine
New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare ...
Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI
More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...
Seeking Alpha2d
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV ...
With nearly 30 years of clinical and real-world use, olanzapine is one of the most commonly prescribed second-generation oral antipsychotics for the treatment of schizophrenia globally ...
Medscape27d
Generic Olanzapine: Health Authority Opportunity or Nightmare?
The notes of 85 outpatients initially prescribed either Zyprexa (38 patients) or a branded generic olanzapine (47 patients) were examined during the study period. Patients prescribed Zyprexa were ...
Medscape2mon
Olanzapine-induced Parkinsonism Associated with Smoking Cessation
2011;68(5):399-401. This case illustrates the need for awareness of the impact of cigarette smoking on medications such as olanzapine. The number of cigarettes smoked daily should be assessed at ...
Seeking Alpha2d
Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI
More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1.